|
1) Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol. 2010; 11: 457-60
|
|
|
|
2) Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118: 3132-42
|
|
|
|
|
|
3) Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118: 3143-50
|
|
|
|
|
|
4) Nam CH, Rabbitts TH. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther. 2006; 13: 15-25
|
|
|
|
|
|
5) Davé UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004; 303: 333
|
|
|
|
|
|
6) Davé UP, Akagi K, Tripathi R, et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 2009; 5: e1000491
|
|
|
|
|
|
7) Schröder ARW, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002; 110: 521-9
|
|
|
|
|
|
8) Wu X, Li Y, Crise B, et al. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003; 300: 1749-51
|
|
|
|
|
|
9) Mitchell RS, Beitzel BF, Schroder ARW, et al. Retroviral integration: ASLV, HIV and MLV show distinct target site preferences. PLoS Biol. 2004; 2: e234
|
|
|
|
|
|
10) Schmidt M, Hoffmann G, Wissler M, et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther. 2001; 12: 743-9
|
|
|
|
|
|
11) Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002; 100: 2737-43
|
|
|
|
|
|
12) Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest. 2007; 117: 2225-32
|
|
|
|
|
|
13) Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007; 117: 2241-9
|
|
|
|
|
|
14) Wang GP, Berry CC, Malani N, et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood. 2010; 115: 4356-66
|
|
|
|
|
|
15) Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007; 117: 2233-40
|
|
|
|
|
|
16) Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360: 447-58
|
|
|
|
|
|
17) Woods NB, Bottero V, Schmidt M, et al. Therapeutic gene causing lymphoma. Nature. 2006; 440: 1123
|
|
|
|
|
|
18) Pike-Overzet K, de Ridder D, Weerkamp F, et al. Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34＋ cells: implications for leukemogenesis in gene therapy. Leukemia. 2007; 21: 754-63
|
|
|
|
|
|
19) Shou Y, Ma Z, Lu T, et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A. 2006; 103: 11730-5
|
|
|
|
|
|
20) Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12: 401-9
|
|
|
|
|
|
21) Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16: 198-204
|
|
|
|
|
|
22) Li Z, Düllmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002; 296: 497
|
|
|
|
|
|
23) Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hemato-poietic cells. Blood. 2005; 106: 2530-3
|
|
|
|
|
|
24) Kustikova O, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005; 308: 1171-4
|
|
|
|
|
|
25) Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005; 106: 3932-9
|
|
|
|
|
|
26) Kustikova OS, Geiger H, Li Z, et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark“stemness"pathways. Blood. 2007; 109: 1897-907
|
|
|
|
|
|
27) Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: History and perspectives. Gene. 2006; 368: 1-11
|
|
|
|
|
|
28) Morishita K. Leukemogenesis of the EVI1/MEL1 gene family. Int J Hematol. 2007; 85: 279-86
|
|
|
|
|
29) Yuasa H, Oike Y, Iwama A, et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expres-sion. EMBO J. 2005; 24: 1976-87
|
|
|
|
|
|
30) Métais J-Y, Dunbar CE. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther. 2008; 16: 439-49
|
|
|
|
|
|
31) Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007; 128: 669-81
|
|
|
|
|
|
32) Morris CA, Moazed D. Centromere assembly and propagation. Cell. 2007; 128: 647-50
|
|
|
|
|
|
33) Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J. 2006; 273: 3121-35
|
|
|
|
|
|
34) Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem. 2008; 105: 344-52
|
|
|
|
|
|
35) Spensberger D, Delwel R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett. 2008; 582: 2761-7
|
|
|
|
|
|
36) Goyama S, Nitta E, Yoshino, T et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia. 2010; 24: 81-8
|
|
|
|
|
|
37) Kondo Y, Shen L, Ahmed S, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One. 2008; 3: e2037
|
|
|
|
|
|
38) Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326: 818-23
|
|
|
|
|
|
39) Zhou S, Mody D, DeRavin SS, et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood published online(May 10, 2010)
|
|
|
|
|
|
40) Gabriel R, Eckenberg R, Paruzynski A, et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med. 2009; 15: 1431-6
|
|
|
|
|